Eli Lilly and Company (LLY) Stock Forecast, Price & News

21 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Eli Lilly and Company in the last twelve months. There are currently 1 sell rating, 1 hold rating and 19 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" LLY shares.
View LLY analyst ratings or view top-rated stocks.

21 Wall Street analysts have issued 1 year target prices for Eli Lilly and Company's stock. Their LLY share price forecasts range from $278.00 to $640.00. On average, they predict the company's stock price to reach $532.78 in the next year. This suggests that the stock has a possible downside of 2.2%.
View analysts price targets for LLY or view top-rated stocks among Wall Street analysts.

Eli Lilly and Company's stock was trading at $365.84 at the beginning of the year. Since then, LLY stock has increased by 48.9% and is now trading at $544.86.
View the best growth stocks for 2023 here.

The company is scheduled to release its next quarterly earnings announcement on Tuesday, November 7th 2023.
View our LLY earnings forecast.

Eli Lilly and Company (NYSE:LLY) posted its earnings results on Tuesday, August, 8th. The company reported $2.11 earnings per share for the quarter, beating the consensus estimate of $1.98 by $0.13. The company had revenue of $8.31 billion for the quarter, compared to the consensus estimate of $7.58 billion. Eli Lilly and Company had a trailing twelve-month return on equity of 65.00% and a net margin of 22.01%. The business's revenue was up 28.1% on a year-over-year basis. During the same period in the previous year, the business posted $1.25 EPS.
Read the conference call transcript.

Eli Lilly and Company announced a quarterly dividend on Monday, June 26th. Stockholders of record on Tuesday, August 15th will be paid a dividend of $1.13 per share on Friday, September 8th. This represents a $4.52 dividend on an annualized basis and a dividend yield of 0.83%. The ex-dividend date is Monday, August 14th.
Read our dividend analysis for LLY.

ETFs with the largest weight of Eli Lilly and Company (NYSE:LLY) stock in their portfolio include iShares U.S. Pharmaceuticals ETF (IHE), Harbor Health Care ETF (MEDI), Invesco S&P 500 Momentum ETF (SPMO), Horizon Kinetics Medical ETF (MEDX), Goldman Sachs Future Health Care Equity ETF (GDOC), iShares U.S. Healthcare ETF (IYH), Health Care Select Sector SPDR Fund (XLV) and Vanguard Health Care ETF (VHT).

Eli Lilly and Company (NYSE:LLY) pays an annual dividend of $4.52 per share and currently has a dividend yield of 0.82%. The company has been increasing its dividend for 9 consecutive years, indicating the company has a new, but growing committment to grow its dividend. The dividend payout ratio is 62.87%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, LLY will have a dividend payout ratio of 34.48% next year. This indicates that the company will be able to sustain or increase its dividend.
Read our dividend analysis for LLY.

Eli Lilly and Company issued an update on its FY 2023 earnings guidance on Tuesday, August, 8th. The company provided earnings per share guidance of $9.70-$9.90 for the period, compared to the consensus estimate of $8.71. The company issued revenue guidance of $33.40 billion-$33.90 billion, compared to the consensus revenue estimate of $31.44 billion.

399 employees have rated Eli Lilly and Company Chief Executive Officer David A. Ricks on Glassdoor.com. David A. Ricks has an approval rating of 86% among the company's employees.

Based on aggregate information from My MarketBeat watchlists, some companies that other Eli Lilly and Company investors own include Johnson & Johnson (JNJ), Pfizer (PFE), NVIDIA (NVDA), Intel (INTC), Cisco Systems (CSCO), Bristol-Myers Squibb (BMY), Walt Disney (DIS), AT&T (T), Verizon Communications (VZ) and JPMorgan Chase & Co. (JPM).

Eli Lilly and Company trades on the New York Stock Exchange (NYSE) under the ticker symbol "LLY."

Eli Lilly and Company's stock is owned by a number of institutional and retail investors. Top institutional shareholders include Lilly Endowment Inc. (10.64%), PNC Financial Services Group Inc. (5.46%), State Street Corp (3.57%), Capital World Investors (2.83%), Bank Julius Baer & Co. Ltd Zurich (2.01%) and State Farm Mutual Automobile Insurance Co. (1.83%). Insiders that own company stock include Acquisition Corp Kearny, Alonzo Weems, Anne E White, Donald A Zakrowski, Ilya Yuffa, Jackson P Tai, Johna Norton, Lilly Endowment Inc, Marschall S Runge and Patrik Jonsson.
View institutional ownership trends.

Shares of LLY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of LLY stock can currently be purchased for approximately $544.86.

Eli Lilly and Company (NYSE:LLY) has a market capitalization of $517.23 billion and generates $28.54 billion in revenue each year. The company earns $6.24 billion in net income (profit) each year or $7.19 on an earnings per share basis.

The company employs 39,000 workers across the globe.

Eli Lilly and Company's mailing address is LILLY CORPORATE CENTER, INDIANAPOLIS IN, 46285. The official website for the company is www.lilly.com. The company can be reached via phone at (317) 276-2000, via email at johnson_philip_l@lilly.com, or via fax at 317-276-4878.